Drawing for ULTRAGENYX GENE THERAPY

USPTO serial 87806064

ULTRAGENYX GENE THERAPY

Reviewed by CopyMark Law Group

Status 606
Filing date
Status date
Registration date
—
Examiner
WOOD, CAROLINE
Law office
INTENT TO USE SECTION

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with ULTRAGENYX GENE THERAPY?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Anne H. Peck

Anne H. Peck COOLEY LLP1299 PENNSYLVANIA AVENUESUITE 700WASHINGTON, DC 20004

Goods and services

ClassDescriptionStatusFirst use
001Chemical and biochemical products for use in gene delivery technology, namely, nucleic acids, including coding and non-coding deoxyribonucleic acids, plasmids, vectors, promotors, enhancers and other regulatory sequences, all for in-vivo laboratory use in gene therapyACTIVE—
005Pharmaceutical preparations for the treatment of liver, hepatological, cardiovascular, central nervous system, inflammatory, autoimmune, musculoskeletal, ophthalmologic, respiratory, and hematologic diseases and disordersACTIVE—
042Biomedical and scientific research in the fields of genome editing, gene editing, genome engineering, gene modulation, genetic diseases, gene therapy, and cell therapy; product development in the fields of genetic therapies and effectors to regulate, modulate, and characterize disease states; pharmaceutical research and development in the field of gene therapy; conducting clinical trials for others in the field of gene therapy design and delivery; biomedical research in the field of gene therapy design and delivery; gene therapy design and delivery development of biochemical assaysACTIVE—
044Providing medical services, namely, gene therapy design and delivery services being gene therapy medical services in the field of genetic diseases and disorders; providing medical services, namely, gene therapy design and delivery services being gene therapy medical services in the field of liver, hepatological, cardiovascular, central nervous system, endocrine, inflammatory, metabolic, autoimmune, musculoskeletal, neurological, ophthalmologic, respiratory, and hematologic diseases and disordersACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

Latest event (MAB6): The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.

DateCodeEventWhat it means
May 16, 2022MAB6ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
May 16, 2022ABN6ABANDONMENT - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Oct 28, 2021EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Oct 27, 2021EX5GSOU EXTENSION 5 GRANTED—
Oct 6, 2021AITUCASE ASSIGNED TO INTENT TO USE PARALEGAL—
Oct 4, 2021EXT5SOU EXTENSION 5 FILED—
Oct 4, 2021EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Mar 27, 2021EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Mar 25, 2021EX4GSOU EXTENSION 4 GRANTED—
Mar 25, 2021EXT4SOU EXTENSION 4 FILED—
Mar 25, 2021EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Sep 30, 2020EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Sep 28, 2020EX3GSOU EXTENSION 3 GRANTED—
Sep 28, 2020EXT3SOU EXTENSION 3 FILED—
Sep 28, 2020EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Mar 31, 2020EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Mar 27, 2020EX2GSOU EXTENSION 2 GRANTED—
Mar 27, 2020EXT2SOU EXTENSION 2 FILED—
Mar 27, 2020EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Oct 3, 2019EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Oct 1, 2019EX1GSOU EXTENSION 1 GRANTED—
Oct 1, 2019EXT1SOU EXTENSION 1 FILED—
Oct 1, 2019EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Apr 9, 2019NOAMNOA E-MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Feb 12, 2019NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Feb 12, 2019PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Jan 23, 2019NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Jan 4, 2019CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Dec 26, 2018XAECEXAMINER'S AMENDMENT ENTERED—
Dec 26, 2018GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED—
Dec 26, 2018GNEAEXAMINERS AMENDMENT E-MAILED—
Dec 26, 2018CNEAEXAMINERS AMENDMENT -WRITTEN—
Dec 12, 2018TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Dec 11, 2018CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Dec 11, 2018TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Jun 12, 2018GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jun 12, 2018GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jun 12, 2018CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jun 5, 2018DOCKASSIGNED TO EXAMINER—
Mar 2, 2018MDSCNOTICE OF DESIGN SEARCH CODE E-MAILED—
Feb 28, 2018NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Feb 24, 2018NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance